{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:51:39Z","timestamp":1794851499169,"version":"4.9.1"},"reference-count":32,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Despite significant progress in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), the prognosis of patients with relapsed disease remains poor due to the emergence of drug resistance and subsequent disease progression. Identification of novel targets and therapeutic strategies for these diseases represents an urgent need. Here, we report that both MCL and DLBCL are exquisitely sensitive to transcription-targeting drugs, in particular THZ531, a covalent inhibitor of cyclin-dependent kinase 12 (CDK12). By implementing pharmacogenomics and a cell-based drug screen, we found that THZ531 leads to inhibition of oncogenic transcriptional programs, especially the DNA damage response pathway, MYC target genes and the mTOR-4EBP1-MCL-1 axis, contributing to dramatic lymphoma suppression &lt;i&gt;in vitro&lt;\/i&gt;. We also identified de novo and established acquired THZ531-resistant lymphoma cells conferred by over-activation of the MEK-ERK and PI3K-AKT-mTOR pathways and upregulation of multidrug resistance-1 (MDR1) protein. Of note, EZH2 inhibitors reversed resistance to THZ531 by competitive inhibition of MDR1 and, in combination with THZ531, synergistically inhibited MCL and DLBCL growth in vitro. Our study indicates that CDK12 inhibitors, alone or together with EZH2 inhibitors, offer promise as novel effective approaches for difficult-to-treat DLBCL and MCL.<\/jats:p>","DOI":"10.3324\/haematol.2021.278743","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:46:43Z","timestamp":1624506403000},"page":"1119-1130","source":"Crossref","is-referenced-by-count":16,"title":["Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas"],"prefix":"10.3324","volume":"107","author":[{"given":"Jing","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tint","family":"Lwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy C.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo M.","family":"Sotomayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek R.","family":"Duckett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"35562","doi-asserted-by":"crossref","unstructured":"Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene. 2003; 22(56):9007-9021.","DOI":"10.1038\/sj.onc.1207261"},{"key":"35563","doi-asserted-by":"crossref","unstructured":"Dave SS, Fu K, Wright GW. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006; 354(23):2431-2442.","DOI":"10.1056\/NEJMoa055759"},{"key":"35564","doi-asserted-by":"crossref","unstructured":"Hartmann EM, Ott G, Rosenwald A. Molecular biology and genetics of lymphomas. Hematol Oncol Clin North Am. 2008; 22(5):807-823.","DOI":"10.1016\/j.hoc.2008.07.004"},{"key":"35565","doi-asserted-by":"crossref","unstructured":"Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol. 2011; 8(3):219-228.","DOI":"10.1097\/PAP.0b013e3182169948"},{"key":"35566","doi-asserted-by":"crossref","unstructured":"Ren Y, Bi C, Zhao X. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest. 2018; 128(12):5517-5530.","DOI":"10.1172\/JCI122533"},{"key":"35567","doi-asserted-by":"crossref","unstructured":"Hnisz D, Schuijers J, Lin CY. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol Cell. 2015; 58(2):362-370.","DOI":"10.1016\/j.molcel.2015.02.014"},{"key":"35568","doi-asserted-by":"crossref","unstructured":"Loven J, Hoke HA, Lin CY. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013; 153(2):320-334.","DOI":"10.1016\/j.cell.2013.03.036"},{"key":"35569","doi-asserted-by":"crossref","unstructured":"Winter GE, Mayer A, Buckley DL. BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment. Mol Cell. 2017; 67(1):5-18.","DOI":"10.1016\/j.molcel.2017.06.004"},{"key":"35570","doi-asserted-by":"crossref","unstructured":"Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018; 17(5):353-377.","DOI":"10.1038\/nrd.2018.21"},{"key":"35571","doi-asserted-by":"crossref","unstructured":"Smith E, Lin C, Shilatifard A. The super elongation complex (SEC) and MLL in development and disease. Genes Dev. 2011; 25(7):661-672.","DOI":"10.1101\/gad.2015411"},{"key":"35572","doi-asserted-by":"crossref","unstructured":"He N, Liu M, Hsu J. HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. Mol Cell. 2010; 38(3):428-438.","DOI":"10.1016\/j.molcel.2010.04.013"},{"key":"35573","doi-asserted-by":"crossref","unstructured":"Chipumuro E, Marco E, Christensen CL. CDK7 inhibition suppresses superenhancer- linked oncogenic transcription in MYCN-driven cancer. Cell. 2014; 159(5):1126-1139.","DOI":"10.1016\/j.cell.2014.10.024"},{"key":"35574","doi-asserted-by":"crossref","unstructured":"Christensen CL, Kwiatkowski N, Abraham BJ. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 2014; 26(6):909-922.","DOI":"10.1016\/j.ccell.2014.10.019"},{"key":"35575","doi-asserted-by":"crossref","unstructured":"Wang Y, Zhang T, Kwiatkowski N. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell. 2015; 163(1):174-186.","DOI":"10.1016\/j.cell.2015.08.063"},{"key":"35576","doi-asserted-by":"crossref","unstructured":"Pelish HE, Liau BB, Nitulescu II. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature. 2015; 526(7572):273-276.","DOI":"10.1038\/nature14904"},{"key":"35577","doi-asserted-by":"crossref","unstructured":"Zhao X, Ren Y, Lawlor M. BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models. Cancer Cell. 2019; 35(5):752-766.","DOI":"10.1016\/j.ccell.2019.04.005"},{"key":"35578","doi-asserted-by":"crossref","unstructured":"Lui GYL, Grandori C, Kemp CJ. CDK12: an emerging therapeutic target for cancer. J Clin Pathol. 2018; 71(11):957-962.","DOI":"10.1136\/jclinpath-2018-205356"},{"key":"35579","doi-asserted-by":"crossref","unstructured":"Dubbury SJ, Boutz PL, Sharp PA. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation. Nature. 2018; 564(7734):141-145.","DOI":"10.1038\/s41586-018-0758-y"},{"key":"35580","doi-asserted-by":"crossref","unstructured":"Krajewska M, Dries R, Grassetti AV. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat Commun. 2019; 10(1):1757.","DOI":"10.1038\/s41467-019-09703-y"},{"key":"35581","doi-asserted-by":"crossref","unstructured":"Iniguez AB, Stolte B, Wang EJ. EWS\/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma. Cancer Cell. 2018; 33(2):202-216.","DOI":"10.1016\/j.ccell.2017.12.009"},{"key":"35582","doi-asserted-by":"crossref","unstructured":"Johnson SF, Cruz C, Greifenberg AK. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep. 2016; 17(9):2367-2381.","DOI":"10.1016\/j.celrep.2016.10.077"},{"key":"35583","doi-asserted-by":"crossref","unstructured":"Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012; 122(10):3416-3423.","DOI":"10.1172\/JCI61272"},{"key":"35584","doi-asserted-by":"crossref","unstructured":"Campaner S, Amati B. Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance. Cell Div. 2012; 7(1):6.","DOI":"10.1186\/1747-1028-7-6"},{"key":"35585","doi-asserted-by":"crossref","unstructured":"Rohban S, Campaner S. Myc induced replicative stress response: how to cope with it and exploit it. Biochim Biophys Acta. 2015; 1849(5):517-524.","DOI":"10.1016\/j.bbagrm.2014.04.008"},{"key":"35586","doi-asserted-by":"crossref","unstructured":"Silva A, Jacobson T, Meads M. An organotypic high throughput system for characterization of drug sensitivity of primary multiple myeloma cells. J Vis Exp. 2015; 101:e53070.","DOI":"10.3791\/53070"},{"key":"35587","doi-asserted-by":"crossref","unstructured":"Silva A, Silva MC, Sudalagunta P. An ex vivo platform for the prediction of clinical response in multiple myeloma. Cancer Res. 2017; 77(12):3336-3351.","DOI":"10.1158\/0008-5472.CAN-17-0502"},{"key":"35588","doi-asserted-by":"crossref","unstructured":"Zhao X, Lwin T, Silva A. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017; 8:14920.","DOI":"10.1038\/ncomms14920"},{"key":"35589","unstructured":"Wang J, Ye Q, She QB. New insights into 4EBP1- regulated translation in cancer progression and metastasis. Cancer Cell Microenviron. 2014; 1(5):e331."},{"key":"35590","doi-asserted-by":"crossref","unstructured":"Gao Y, Zhang T, Terai H. Overcoming resistance to the THZ series of covalent transcriptional CDK inhibitors. Cell Chem Biol. 2018; 25(2):135-142.","DOI":"10.1016\/j.chembiol.2017.11.007"},{"key":"35591","doi-asserted-by":"crossref","unstructured":"Olson CM, Liang Y, Leggett A. Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype. Cell Chem Biol. 2019; 26(6):792-803.","DOI":"10.1016\/j.chembiol.2019.02.012"},{"key":"35592","doi-asserted-by":"crossref","unstructured":"Cihalova D, Staud F, Ceckova M. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS- 032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro. Cancer Chemother Pharmacol. 2015; 76(1):105-116.","DOI":"10.1007\/s00280-015-2772-1"},{"key":"35593","doi-asserted-by":"crossref","unstructured":"Zhang P, de Gooijer MC, Buil LC. ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors. Int J Cancer. 2015; 137(8):2007-2018.","DOI":"10.1002\/ijc.29566"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.278743\/73449","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.278743\/74400","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10307\/73449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:59:50Z","timestamp":1794045590000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.278743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.278743","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,24]]}}}